Cardioviva™ supports healthy cholesterol and inflammatory markers in a randomized controlled trial
Montréal, Québec - Micropharma Limited, a pioneer in the development of innovative and effective probiotics, released the results today of a second gold standard clinical trial evaluating the efficacy of Cardioviva™. The study was aimed at evaluating the cholesterol-lowering efficacy and the mechanism of action of Lactobacillus reuteri NCIMB 30242 (Cardioviva™) capsules in hypercholesterolemic adults. A total of 127 subjects completed a randomized, double-blind, placebo-controlled, parallel-arm, multicenter study. Subjects were randomized to consume L. reuteri NCIMB 30242 capsules or placebo capsules over a 9-week intervention period. The primary outcome was LDL-C relative to placebo at the study end point. L. reuteri NCIMB 30242 capsules changed LDL-C by 11.64% (P<0.001), total cholesterol by 9.14%, (P<0.001), non-HDL-cholesterol (non-HDL-C) by 11.30% (P<0.001) and apoB-100 by 8.41% (P=0.002) relative to placebo. The ratios of LDL-C/HDL-cholesterol (HDL-C) and apoB-100/apoA-1 were changed by 13.39% (P=0.006) and 9.00% (P=0.026), respectively, relative to placebo. Triglycerides and HDL-C were unchanged. High-sensitivity C-reactive protein and fibrinogen were changed by 1.05?mg/l (P=0.005) and 14.25% (P=0.004) relative to placebo, respectively. Mean plasma deconjugated bile acids were increased by 1.00?nmol/l (P=0.025) relative to placebo, whereas plasma campesterol, sitosterol and stigmasterol were decreased by 41.5%, 34.2% and 40.7%, respectively. The results indicate that the deconjugation of intraluminal bile acids results in altered absorption of non-cholesterol sterols and indicate that L. reuteri NCIMB 30242 capsules may be useful as an adjunctive therapy for treating hypercholesterolemia. The results of the study will appear in an upcoming publication in the European Journal of Clinical Nutrition and has been published in advance online:
Cardioviva™ is a probiotic bacteria of the genus and species Lactobacillus reuteri. It acts through its capacity to produce bile salt hydrolase (BSH) enzyme and supports healthy cholesterol levels by decreasing absorption of dietary cholesterol and increasing metabolic elimination of cholesterol from the blood. Cardioviva™ has been shown to effectively support healthy total cholesterol (TC)*, low-density lipoprotein cholesterol (LDL-C), apolipoprotien B 100 (ApoB-100), and non-high density lipoprotein cholesterol (non-HDL-C) in human clinical trials. In addition to its cholesterol-lowering properties, Cardioviva™ provides traditional probiotic benefits such as improved digestive health and immune function.
*For the maintenance of cholesterol levels that are within the normal range.
Micropharma and its partners hold exclusive worldwide rights to develop and commercialize Cardioviva™ for all indications.
Micropharma Limited, headquartered in Montreal, Quebec, is bringing a new approach to the development of OTC healthcare products, medical foods, and biotherapeutics. Through innovative research and development, Micropharma is creating scientifically powerful products. Micropharma applies a pathophysiological driven method to developing probiotic and enzyme therapies by focusing first on the heath concern and then developing the effective products to support heath in that condition. This method is supported by extensive research and development to ensure that we are providing the most effective product to consumers. Micropharma is currently addressing probiotic support for some of the World’s most difficult and costly diseases including heart disease, diabetes, chronic liver disease, and hypertension. Our experience research team is supported by a growing business development and marketing group. By fostering strategic partnerships with leading manufacturers, distributors, and retailers, Micropharma is building a global network to deliver innovative and effective health-care solutions.